JP2016190870A5 - - Google Patents

Download PDF

Info

Publication number
JP2016190870A5
JP2016190870A5 JP2016152831A JP2016152831A JP2016190870A5 JP 2016190870 A5 JP2016190870 A5 JP 2016190870A5 JP 2016152831 A JP2016152831 A JP 2016152831A JP 2016152831 A JP2016152831 A JP 2016152831A JP 2016190870 A5 JP2016190870 A5 JP 2016190870A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016152831A
Other versions
JP2016190870A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016190870A publication Critical patent/JP2016190870A/ja
Publication of JP2016190870A5 publication Critical patent/JP2016190870A5/ja
Withdrawn legal-status Critical Current

Links

JP2016152831A 2008-08-15 2016-08-03 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤 Withdrawn JP2016190870A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8942208P 2008-08-15 2008-08-15
US61/089,422 2008-08-15
US27333209P 2009-08-03 2009-08-03
US61/273,332 2009-08-03
US23172509P 2009-08-06 2009-08-06
US61/231,725 2009-08-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014092883A Division JP6034327B2 (ja) 2008-08-15 2014-04-28 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018070898A Division JP6473532B2 (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070899A Division JP2018104469A (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤

Publications (2)

Publication Number Publication Date
JP2016190870A JP2016190870A (ja) 2016-11-10
JP2016190870A5 true JP2016190870A5 (ja) 2017-03-30

Family

ID=41666602

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2011523004A Active JP5770629B2 (ja) 2008-08-15 2009-08-14 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2014092883A Active JP6034327B2 (ja) 2008-08-15 2014-04-28 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2016152831A Withdrawn JP2016190870A (ja) 2008-08-15 2016-08-03 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070899A Withdrawn JP2018104469A (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070898A Active JP6473532B2 (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2019126707A Withdrawn JP2019163340A (ja) 2008-08-15 2019-07-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2021018125A Withdrawn JP2021073297A (ja) 2008-08-15 2021-02-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2022111842A Withdrawn JP2022132383A (ja) 2008-08-15 2022-07-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2023209257A Withdrawn JP2024015361A (ja) 2008-08-15 2023-12-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2025080475A Pending JP2025109853A (ja) 2008-08-15 2025-05-13 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011523004A Active JP5770629B2 (ja) 2008-08-15 2009-08-14 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2014092883A Active JP6034327B2 (ja) 2008-08-15 2014-04-28 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018070899A Withdrawn JP2018104469A (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2018070898A Active JP6473532B2 (ja) 2008-08-15 2018-04-02 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2019126707A Withdrawn JP2019163340A (ja) 2008-08-15 2019-07-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2021018125A Withdrawn JP2021073297A (ja) 2008-08-15 2021-02-08 経口投与に好適なgc−c受容体アゴニストポリペプチドの安定な固体製剤
JP2022111842A Withdrawn JP2022132383A (ja) 2008-08-15 2022-07-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2023209257A Withdrawn JP2024015361A (ja) 2008-08-15 2023-12-12 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤
JP2025080475A Pending JP2025109853A (ja) 2008-08-15 2025-05-13 経口投与に好適なgc-c受容体アゴニストポリペプチドの安定な固体製剤

Country Status (32)

Country Link
US (7) US20120213846A1 (ja)
EP (2) EP3701962A1 (ja)
JP (10) JP5770629B2 (ja)
KR (11) KR101704832B1 (ja)
CN (5) CN117530912A (ja)
AU (1) AU2009282446B2 (ja)
BR (1) BRPI0917807A2 (ja)
CA (1) CA2732892C (ja)
CL (1) CL2011000314A1 (ja)
CO (1) CO6351746A2 (ja)
CY (1) CY1122801T1 (ja)
DK (1) DK2328601T3 (ja)
EA (1) EA201170337A1 (ja)
ES (1) ES2785980T3 (ja)
GE (1) GEP20156209B (ja)
HK (1) HK1219062A1 (ja)
HR (1) HRP20200512T2 (ja)
HU (1) HUE049023T2 (ja)
IL (1) IL211028A (ja)
LT (1) LT2328601T (ja)
MX (4) MX385591B (ja)
NZ (1) NZ591713A (ja)
PE (2) PE20110543A1 (ja)
PH (1) PH12015501579B1 (ja)
PL (1) PL2328601T3 (ja)
PT (1) PT2328601T (ja)
RS (1) RS60101B1 (ja)
SG (1) SG193801A1 (ja)
SI (1) SI2328601T1 (ja)
SM (1) SMT202000179T1 (ja)
WO (1) WO2010019266A2 (ja)
ZA (1) ZA201101523B (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
AU2009322285B2 (en) 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
HUE034190T2 (en) * 2009-11-03 2018-01-29 Ironwood Pharmaceuticals Inc Linaclitaxel for the treatment of chronic constipation
PH12012500916B1 (en) 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
EP2509992B1 (en) 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
HRP20192207T1 (hr) * 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
WO2012034068A1 (en) * 2010-09-11 2012-03-15 Ironwood Pharmaceuticals, Inc. Treatment of constipation-predominant irritable bowel syndrome
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US9650417B2 (en) 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
HUE032237T2 (en) * 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
BR112014007753B1 (pt) * 2011-09-30 2021-07-06 Astellas Pharma Inc. composição farmacêutica granular, formulação e método para produção
WO2014088623A1 (en) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Linaclotide compositions
EP2950803A1 (en) * 2013-01-30 2015-12-09 Sandoz AG Crystalline form of linaclotide
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US10272131B2 (en) 2014-08-11 2019-04-30 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
CN104569245A (zh) * 2014-12-08 2015-04-29 江苏泰洁检测技术有限公司 一种工作场所脂肪族胺类中环己胺浓度测定方法
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
EP3302440B1 (en) * 2015-06-05 2021-01-06 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
EP3558337A1 (en) 2016-12-21 2019-10-30 Ironwood Pharmaceuticals, Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
CN107669700A (zh) * 2017-09-14 2018-02-09 湖南晓林生物科技发展有限公司 一种治疗溃疡性结肠炎的药物及其制备方法
WO2020012243A2 (en) 2018-07-09 2020-01-16 Abbott Laboratories Gmbh Pharmaceutical composition containing a peptide
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN112121021B (zh) * 2019-06-24 2022-03-25 深圳翰宇药业股份有限公司 一种含利那洛肽的药物组合物及其制备方法
JP2021104941A (ja) * 2019-12-26 2021-07-26 ニプロ株式会社 薬物高含有量錠剤及びその製造方法
JP7599014B2 (ja) * 2020-06-30 2024-12-12 オクヴィルク,ゼレン グアニル酸シクラーゼc(gucy2c)アゴニストおよび短鎖脂肪酸またはそのプロドラッグの組み合わせを含む医薬組成物
CN113616616A (zh) * 2021-09-07 2021-11-09 四川国为制药有限公司 一种利那洛肽胶囊制剂及其制备方法
US20230106943A1 (en) * 2021-09-17 2023-04-06 Peptilogics, Inc. Engineered antimicrobial peptides and usage thereof
CN114632141B (zh) * 2022-04-19 2023-08-01 苏州中化药品工业有限公司 一种含利那洛肽的药物组合物、胶囊制剂及其制备方法
CN116672309A (zh) * 2023-07-26 2023-09-01 北京普诺旺康医药科技有限公司 干混悬药物组合物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
CZ433898A3 (cs) 1996-07-03 1999-04-14 Alza Corporation Nevodné protické peptidové formulace
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US20020151502A1 (en) * 1997-10-09 2002-10-17 Albert Sattin Tri-peptides for neurological and neurobehavior applications
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP1098636A1 (en) 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
EP1109728A1 (de) * 1998-09-04 2001-06-27 GAPLAST GmbH Behälter
ID29085A (id) 1998-11-27 2001-07-26 Kanji Takada Suatu formulasi oral untuk penghantaran obat gastrointestinal
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
EP1351704B1 (en) 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1458407A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
CN1726012A (zh) 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE390142T1 (de) 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd Synergistische zusammensetzung zur behandlung von diabetes mellitus
ATE553747T1 (de) 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
CN101094651B (zh) 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1996218A4 (en) 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2661521C (en) 2006-08-31 2016-04-12 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
EP2114379A2 (en) 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
EP2650303A1 (en) 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
AU2009322285B2 (en) 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CA2770334A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide

Similar Documents

Publication Publication Date Title
BR112018068177A2 (ja)
BR112019002665A2 (ja)
BR112018004986A2 (ja)
BR112019008128A2 (ja)
BR112019001100A2 (ja)
BR112019001429A2 (ja)
BR212018070320U2 (ja)
BR112019011044B1 (pt) Compostos de pirazol substituído, seu uso, e composição farmacêutica
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019003296B1 (pt) Método para acionamento automático de um modo atrasado direto
BR112019001236B1 (pt) Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa
BR112019000061B1 (pt) Comutação e modulação de splicing de pré-mrna compreendendo porções de arcabouço bicíclico, com características melhoradas para o tratamento de distúrbios genéticos
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR112018072681B1 (pt) Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica
BR112018071288B1 (pt) Domínio de ligação de carreador de proteína sérica de afinidade modificada, molécula de anticorpo e composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019013609B1 (pt) Método e aparelho de processamento de informação de mídia de streaming
BR112019006736A2 (ja)
BR112019003108A2 (ja)
BR202016021748U2 (ja)
BE2016C016I2 (ja)
CN303536207S (ja)
CN303588289S (ja)